WO2005054863A3 - Agents diagnostiques et therapeutiques pour pathologies associees au canal k+ de type girk (girk3) - Google Patents

Agents diagnostiques et therapeutiques pour pathologies associees au canal k+ de type girk (girk3) Download PDF

Info

Publication number
WO2005054863A3
WO2005054863A3 PCT/EP2004/012784 EP2004012784W WO2005054863A3 WO 2005054863 A3 WO2005054863 A3 WO 2005054863A3 EP 2004012784 W EP2004012784 W EP 2004012784W WO 2005054863 A3 WO2005054863 A3 WO 2005054863A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
girk
therapeutics
diagnostics
protein
Prior art date
Application number
PCT/EP2004/012784
Other languages
English (en)
Other versions
WO2005054863A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2005054863A2 publication Critical patent/WO2005054863A2/fr
Publication of WO2005054863A3 publication Critical patent/WO2005054863A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un canal K+ de type GIRK humain, qui est associé à des pathologies cardio-vasculaires, à des affections dermatologiques, à des affections gastro-entérologiques, au cancer, aux inflammations, à des maladies métaboliques, à des maladies hématologiques, à des affections neurologiques et à des affections urologiques. L'invention concerne également des tests permettant d'identifier des composés utiles dans le traitement ou la prévention de pathologies cardio-vasculaires, d'affections dermatologiques, d'affections gastro-entérologiques, de cancers, d'inflammations, de maladies métaboliques, de maladies hématologiques, d'affections neurologiques et d'affections urologiques. L'invention concerne par ailleurs des composés se fixant au canal K+ de type GIRK et/ou activant ou inhibant l'activité dudit canal K+ de type GIRK, de même que des compositions pharmaceutiques comprenant de tels composés.
PCT/EP2004/012784 2003-11-22 2004-11-11 Agents diagnostiques et therapeutiques pour pathologies associees au canal k+ de type girk (girk3) WO2005054863A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03027005 2003-11-22
EP03027005.2 2003-11-22

Publications (2)

Publication Number Publication Date
WO2005054863A2 WO2005054863A2 (fr) 2005-06-16
WO2005054863A3 true WO2005054863A3 (fr) 2005-08-25

Family

ID=34639262

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/012784 WO2005054863A2 (fr) 2003-11-22 2004-11-11 Agents diagnostiques et therapeutiques pour pathologies associees au canal k+ de type girk (girk3)

Country Status (1)

Country Link
WO (1) WO2005054863A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744324A (en) * 1993-05-21 1998-04-28 California Institute Of Technology Nucleic acids encoding potassium channels which form inward rectifier, G-protein activated, mammalian, heteromultimeric, potassium channels and uses thereof
WO2001098351A2 (fr) * 2000-06-16 2001-12-27 Incyte Genomics, Inc. Recepteurs couples a la proteine g
WO2002079434A2 (fr) * 2001-03-29 2002-10-10 Deltagen, Inc. Souris transgeniques presentant des disruptions du gene kir3.3 du canal potassique
WO2003080639A1 (fr) * 2002-03-20 2003-10-02 Sagres Discovery, Inc. Nouvelles compositions et methodes destinees au traitement des cancers associes a l'expression modifiee de kcnj9

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744324A (en) * 1993-05-21 1998-04-28 California Institute Of Technology Nucleic acids encoding potassium channels which form inward rectifier, G-protein activated, mammalian, heteromultimeric, potassium channels and uses thereof
WO2001098351A2 (fr) * 2000-06-16 2001-12-27 Incyte Genomics, Inc. Recepteurs couples a la proteine g
WO2002079434A2 (fr) * 2001-03-29 2002-10-10 Deltagen, Inc. Souris transgeniques presentant des disruptions du gene kir3.3 du canal potassique
WO2003080639A1 (fr) * 2002-03-20 2003-10-02 Sagres Discovery, Inc. Nouvelles compositions et methodes destinees au traitement des cancers associes a l'expression modifiee de kcnj9

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VAUGHN JEANNETTE ET AL: "Genomic structure and expression of human KCNJ9 (Kir3.3/GIRK3)", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 274, no. 2, 2 August 2000 (2000-08-02), pages 302 - 309, XP002324142, ISSN: 0006-291X *

Also Published As

Publication number Publication date
WO2005054863A2 (fr) 2005-06-16

Similar Documents

Publication Publication Date Title
WO2005093092A3 (fr) Diagnostic et traitement de maladies associees au recepteur 44 couple aux proteines g (gpr44)
WO2005114207A3 (fr) Diagnostic et traitement de maladies associees a l'aminopeptidase n (anpep)
WO2005103684A3 (fr) Diagnostics et methodes therapeutiqeus pour des maladies associees au recepteur 1 de la chimiokine cx3c
WO2005022146A3 (fr) Diagnostics et traitements de maladies associees a la kallikreine 13 (klk13)
WO2005040828A3 (fr) Agents de diagnostic et de traitement des maladies associees au recepteur 49 couple aux proteines g (gpr49)
WO2005075675A3 (fr) Outils de diagnostic et de traitement de maladies associees a la cysteine protease putative 1 (prsc1)
WO2005076007A3 (fr) Diagnostics et traitements de maladies associees au recepteur p2y12 couple a la proteine g (p2y12)
WO2004097358A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a la serine protease 2 transmembranaire humaine (tmprss2)
WO2005022164A3 (fr) Agents diagnostiques et agents therapeutiques destines a des maladies associees a la kallikreine 8 (klk8)
WO2005093091A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 26 couple a la proteine g (gpr26)
WO2005031345A3 (fr) Diagnostic et therapeutique de maladies associees au recepteur couple a la proteine g adipor2 (adipor2)
WO2005054848A3 (fr) Diagnostics et therapeutique pour maladies associees au canal potassique a rectification entrante couple a une proteine (girk2)
WO2004038405A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 43 couple a la proteine g (gpr43)
WO2005054863A3 (fr) Agents diagnostiques et therapeutiques pour pathologies associees au canal k+ de type girk (girk3)
WO2005073729A3 (fr) Diagnostic et traitement de maladies associees au recepteur p2y11 couple a une proteine g (p2y11)
WO2005050197A3 (fr) Diagnostics et therapeutiques de maladies associees au canal potassique girk4 (girk4) a rectification interieure couple a une proteine
WO2005040825A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 20 couple a la proteine g (gpr20)
WO2006013013A3 (fr) Agents pour le diagnostic et le traitement de maladies associees a la proteine protectrice pour la beta-galactosidase (ppgb)
WO2005075983A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a un recepteur nucleaire humain nr4a3 (nr4a3)
WO2005054867A3 (fr) Diagnostics et therapeutique pour maladies associees au canal potassique de la sous-famille k, membre 5 (kcnk5)
WO2004038421A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 41 couple a une proteine g humaine (gpr41)
WO2004097034A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a la serine protease 4 transmembranaire humaine (tmprss4)
WO2004099248A3 (fr) Produits de diagnostic et de traitement de maladies associees au recepteur agtr2 couple aux proteines g (agtr2)
WO2005026719A3 (fr) Diagnostic et traitement de maladies associees au transporteur de cations organiques slc22a3 (slc22a3)
WO2005052586A3 (fr) Elements de diagnostic et de therapie pour des maladies associees au canal potassique, sous famille k et element 3 (kcnk3)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase